Drug Profile
Numidargistat - Calithera Biosciences
Alternative Names: CB-1158; INCB 001158; INCB 01158Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Mars Symbioscience
- Developer Calithera Biosciences; Incyte Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action Arginase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Multiple myeloma; Solid tumours
Most Recent Events
- 20 Mar 2023 Incyte Corporation terminates a phase I/II trial in Multiple myeloma (Second-line therapy or greater, Combination therapy) in USA, Spain and Germany (PO) due to recruitment difficulties (NCT03837509) (EudraCT2018-004076-35)
- 31 Dec 2022 Incyte Corporation terminates its License Agreement with Calithera Biosciences for Numidargistat
- 28 Nov 2022 Incyte Corporation completes a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA, Belgium and the UK (PO) (NCT03314935) (EudraCT2017-002904-29)